PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States.
The companyâs cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015.
PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Founded
1996
Employees
2
Loading company sections...
⚡
Core Efficiency
D/E Ratio?
0.06
📊
Profitability Ratios
Current Ratio?
7.68
Loading comparison...
Earnings Calendar
Filing history and next expected filing date
Aug 11, 2025
10-KQ4 20257d after period end
Mar 17, 2025
10-QQ3 202510d after period end
Sep 17, 2024
10-QQ1 20257d after period end
Data Freshness
Financial Data
1mo ago
Latest filing: 2026-03-17
SEC Metadata
2mo ago
Latest filing: 2024-08-13
Recent Insider Trades
Abecassis Michael M — Purchase (Derivative) 119,170 shares at $0.00 on 2026-03-31
SCHECHTER JONATHAN — Purchase (Derivative) 119,170 shares at $0.00 on 2026-03-31